Background
==========

Kidney transplantation is considered the treatment of choice for end stage renal disease (ESRD), which is in part due to availability of more effective immunosuppressive regimens. The mammalian target of rapamycin (mTOR) inhibitors, rapamycin, also known as sirolimus, and everolimus, have been recently widely utilized in immunosuppressive regimens providing adequate immunosuppression and avoiding nephrotoxic side effects of calcineurin inhibitor therapy \[[@B1]-[@B4]\]. However, prolonged graft survival leads to increased incidence of complications related to both immunosuppression and drug toxicity. Drug induced immunosuppression halts tumor surveillance leading to an increase in tumor development. Epidemiologic studies show that posttransplant lymphoproliferative disorder (PTLD) and skin cancers increased most dramatically following kidney transplantation \[[@B5]-[@B8]\]. In addition to immunosuppression, sirolimus exhibits antineoplastic properties in vivo \[[@B9]\] and newer rapamycin analogs have been evaluated in clinical trials for treatment of renal cell carcinoma \[[@B10]\]. Clinical experience with these medications is limited; but it has been shown to cause regression of PTLD and Kaposi sarcoma \[[@B11]-[@B14]\]. The incidence of pulmonary toxicity in patients on mTOR inhibitors has been reported to be up to 11% \[[@B15],[@B16]\]. Risk factors for the development of sirolimus-associated pneumonitis include higher dose, greater trough levels and older age \[[@B17]\]. While the contribution of other causes in the setting of mTOR inhibitor induced immunosuppression is difficult to separate from direct drug toxicity, a range of pulmonary histopathologic changes has been suggested as manifestations of drug toxicity. Depending on biopsy modality these include descriptive diagnoses or better-defined histological patterns such as organizing pneumonia and diffuse alveolar hemorrhage \[[@B15],[@B16],[@B18]-[@B20]\]. Pulmonary hemorrhage has been reported as a sole histological finding \[[@B21]\] but also in combination with others \[[@B18]\]. Other rare pulmonary manifestations include pulmonary alveolar proteinosis \[[@B22]\], desquamative interstitial pneumonitis \[[@B23]\], hypersensitivity pneumonitis \[[@B24]\], necrotizing granulomas and vasculitis \[[@B25]\], diffuse alveolar damage \[[@B26]\] and non-necrotizing granulomas \[[@B19]\]. Since the reported histological manifestations are not specific for sirolimus toxicity, drug discontinuation with or without steroid therapy is the mainstay of treatment in suspected cases and typically leads to resolution of symptoms within 2 to 4 months \[[@B18]\]. To the best of our knowledge, only small series or case reports describe pulmonary pathology in renal allograft recipients and the concept of sirolimus-associated pulmonary complications is still evolving. Therefore, the goals of this study were to provide a systematic review of pulmonary histological findings in the setting of kidney transplantation and elucidate the possible contribution of the current immunosuppressive regimens to the spectrum of the observed histological changes.

Material and methods
====================

A laboratory information system database search from January 2002 to September 2010 revealed 28 renal allograft recipients who required a lung biopsy for respiratory symptoms. In total, 42 biopsies were performed, including 8 (19%) video-assisted thoracoscopic biopsies, 28 (67%) endobronchial biopsies, 5 (12%) needle biopsies, and 1 (2%) mediastinal lymph node biopsy. Sixteen (38%) biopsies were nondiagnostic. Biopsies were considered non-diagnostic if they had limited tissue or minimal nonspecific histological changes such as chronic inflammation or focal interstitial fibrosis. Hematoxylin-eosin (H&E) stained slides (range, 1-19; mean, 3 slides) and special stains for microorganisms including Gomori methenamine silver, Ziehl-Neelsen and gram stains, performed on formalin-fixed, paraffinembedded tissue were re-examined. The radiology studies including chest computed tomography (CT) were reviewed in respect to localized versus diffuse changes. Localized lesions included nodules or masses while the diffuse lesions were comprised of diffuse or patchy bilateral ground glass opacities, reticular densities, bilateral consolidations, mosaic attenuation, and traction bronchiectasis. Retrospective analysis of electronic clinical records and correlation with histological findings and type of immunosuppressive therapy were performed. The electronic medical records were reviewed with special attention for evidence of systemic diseases and infectious complications including microbiological cultures and serologies for viral and fungal pathogens. Review of immunosuppressive regimens included an active list of medications pre-and post-lung biopsy. Clinical and pathological findings were analyzed utilizing mean ± SD for continuous variables, and number or percentage for categorical variables. Comparisons were performed using Yates\' chi-square test for categorical variables, and the two-sample *t*test for continuous variables. The study was approved by The Ohio State Biomedical Sciences Institutional Review Board in compliance with Health Insurance Portability and Accountability Act regulations.

Results
=======

Clinicopathological findings in patients with kidney transplant
---------------------------------------------------------------

The main clinical and pathological findings are summarized in Table [1](#T1){ref-type="table"}. Twenty-eight of 2140 (1.3%) kidney transplant recipients over the period of 105 months underwent a lung biopsy for pulmonary symptoms. They included 18 males and 10 females with an age range from 25 to 77 years old (mean age of 53 years). The time from kidney transplantation to lung biopsy ranged from 4 to 345 months (mean 81 months). In 19 cases (68%) the biopsies were performed to obtain tissue diagnosis for localized lesions, and in 9 cases (32%) for diffuse lesions. The majority of patients (18/28 or 64%) received a deceased donor kidney. Eight patients (29%) received kidneys from living related donors; two patients (7%) received kidneys from living unrelated donors. One patient received three transplants, including two cadaveric and one living related. Twenty-five (89%) patients had kidney-only transplant, while three patients (11%) had a combined kidney and pancreas transplantation. The most common cause of ESRD was diabetic nephropathy (10/28; 36%). Other causes included hypertension (2/28; 7%), polycystic kidney disease (2/28; 7%), glomerulonephritis (4/28; 14%), granulomatosis with polyangiitis (Wegner\'s granulomatosis) (1/28; 4%), IgA nephropathy (1/28; 4%), chronic reflux (1/28; 4%), p-ANCA-positive microscopic polyangiitis (1/28; 4%), and interstitial nephritis (1/28; 4%).

###### 

Clinical pathological findings in kidney transplant recipients

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
        Age, years   Gender   Kidney disease   Transplant type   Time, mos   Sirolimus trough levels, mean(range), ng/ml   Other immuno-suppressants   Clinical radiological presentation                                              Biopsy type   Pathological findings
  ----- ------------ -------- ---------------- ----------------- ----------- --------------------------------------------- --------------------------- ------------------------------------------------------------------------------- ------------- -----------------------
  1\*   49           M\*\*    DM1              K/Cad             11          11.7(6.2-18.7)                                C/P                         Bilateral mass-like consolidations                                              EB            ND

                                                                                                                                                                                                                                                     

  2     25           F        DM1              K/Cad             20                                                        C/MY/D                      Patchy bilateral consolidations                                                 EB            BCLPD

                                                                                                                                                                                                                                                     

  3     71           M        PCKD             K/Cad             36                                                        C/D                         Mediastinal lymphadenopathy                                                     EB LNB        DLBCL

                                                                                                                                                                                                                                                     

  4     58           F        DM2              K/Cad             5           8.8(4.0-17.1)                                 C/P                         Respiratory failure Diffuse ground glass opacities                              EB THB        Hemorrhage

                                                                                                                                                                                                                                                     

  5     47           F        HTN              K/Cad             210                                                       C/MY/P                      Respiratory failure, loculated pneumonia                                        EB            Necrosis\
                                                                                                                                                                                                                                                     Fibrin

                                                                                                                                                                                                                                                     

  6     72           M        DM2              K/Cad             20          4.8(2.0-8.2)                                  C/P                         Spiculated lung lesion                                                          NB            SQC

                                                                                                                                                                                                                                                     

  7     77           M                         K/Cad             116                                                       C/D                         Pulmonary nodule                                                                EB            SQC

                                                                                                                                                                                                                                                     

  8     71           M        pANCA            K/Cad             10          15.1                                          C/P                         Right lower lobe mass                                                           EB            ND

                                                                                                                                                                                                                                                     

                                                                                                                                                       Diffuse ground glass opacities                                                                

                                                                                                                                                                                                                                                     

  9     48           F        NA               K/Cad             32          NA                                            MY/P                        Left lower lobe nodule                                                          EB            Necrosis\
                                                                                                                                                                                                                                                     Fibrin

                                                                                                                                                                                                                                                     

  10    39           M        GN               K/Cad             80          10.2(8.1-11.8)                                C/P                         Respiratory failure, diffuse ground glass opacities with crazy paving pattern   THB\          Hemorrhage PAP\
                                                                                                                                                                                                                                       EB            OP

                                                                                                                                                                                                                                                     

  11    45           F        NA               K/Cad, LR         345                                                       C/P                         Collapsed lung, pneumonia                                                       EB            OP

                                                                                                                                                                                                                                                     

  12    58           F        HTN              K/Cad             24          19.7                                          C/P                         Respiratory failure, diffuse ground glass opacities                             EB THB        Hemorrhage

                                                                                                                                                                                                                                                     

  13    44           F        DM2              K/LR              36          5.3(3.2-6.9)                                  C/P                         Mediastinal lymphadenopathy, patchy ground glass opacities                      EB            ND

                                                                                                                                                                                                                                                     

  14    46           M        WG               K/LR              175                                                       C/MY/P                      Diffuse ground glass opacities, lung nodules                                    EB\           Hemorrhage\
                                                                                                                                                                                                                                       NB            Capillaritis

                                                                                                                                                                                                                                                     

  15    49           F        DM               K                 73          8.1(4.3-11.6)                                 C/P                         Bilateral ground glass opacification with right lower lobe consolidation        EB            OP

                                                                                                                                                                                                                                                     

  16    34           F        DM1              KP/Cad            19          4.2(2.4-6.7)                                  C/P                         Respiratory failure, diffuse ground glass opacities                             THB           DAD Hemorrhage

                                                                                                                                                                                                                                                     

  17    43           M        DM1              KP                41          4.4                                           C/P                         Nodular right lower lobe infiltrate                                             EB            ND

                                                                                                                                                                                                                                                     

  18    69           M        DM2              K/LU              4           11.0(5.0-14.9)                                C/P                         Bilateral lung nodules and mediastinal lymphadenopathy                          NB            BCLPD

                                                                                                                                                                                                                                                     

  19    71           M        IgA              K/LR              114                                                       C/P                         Dyspnea, diffuse ground glass opacities                                         EB            PAP

                                                                                                                                                                                                                                                     

  20    60           M        GN               K/LR              89                                                        C/MY/D                      Lung nodule                                                                     EB            ND

                                                                                                                                                                                                                                                     

  21    65           M                         K/LR              41          6.8(2.8-12.0)                                 MA/P                        Bilateral hypermetabolic lung nodules                                           THB           PJ granulomas

                                                                                                                                                                                                                                                     

  22    60           M        GN               K/LR              66                                                        C/P                         Lung mass                                                                       THB           ADC

                                                                                                                                                                                                                                                     

  23    52           M        DM1              KP/Cad            73                                                        C/P                         Lung mass                                                                       EB            SQC

                                                                                                                                                                                                                                                     

  24    34           M        GN               K/Cad             38          10.2(6.1-14.3)                                C/P                         Bilateral ground glass opacities\                                               EB            Fibrin\
                                                                                                                                                       Loculated right sided pleural effusion                                                        Necrosis

                                                                                                                                                                                                                                                     

  25    36           F        NA               K                 180                                                       C/P                         Bilateral lung nodules, lymphadenopathy                                         THB NB        LYG

                                                                                                                                                                                                                                                     

  26    62           M        IN               K/LR              115                                                       C/P                         Lung mass                                                                       NB            ADC

                                                                                                                                                                                                                                                     

  27    53           M        PCKD             K/LU              61          2.0                                           MA/P                        Lung nodule, pleural effusion                                                   EB            ND

                                                                                                                                                                                                                                                     

  28    32           M        CR               K/LU              220         8.6(4.4-13.2)                                 C/MA/P                      Dyspnea, patchy ground glass opacities                                          EB            OP
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

(\*) - the cases are arranged in chronological order; (\*\*)-*M*male; *F*female; *DM*diabetes mellitus; *PCKD*polycystic kidney disease; *HTN*hypertension; *p-ANCA*p-ANCA vasculitis; *GN*glomerulonephritis; *WG*Wegner\'s granulomatosis; *IgA*IgA nephropathy; *IN*interstitial nephritis; *CR*chronic reflux; *K*kidney transplant; *KP*kidney and pancreas transplant; *Cad*cadaveric kidney; *LR*living related kidney; *LU*living unrelated kidney; *EB*endobronchial biopsy; *THB*thoracoscopic biopsy; *NB*needle biopsy; *LNB*lymph node biopsy; *C*cyclosporine; *P*prednisone; *D*dexamethasone; *MY*mycophenolate mofetil; *MA*mycophenolic acid; *ND*not diagnostic; *SQC*squamous cell carcinoma; *ADC*adenocarcinoma; *BCLPD*B-cell lymphoproliferative disorder; *DLBCL*diffuse large B-cell lymphoma; *LYG*lymphomatoid granulomatosis; *OP*organizing pneumonia; *DAD*diffuse alveolar damage; *PJ*Pneumocystis jiroveci; *PAP*pulmonary alveolar proteinosis; *NA*not available

Neoplasia on lung biopsy was identified in 9 (0.4%) of 2140 kidney transplant recipients. Among 9 cases there were 5 non-small cell carcinomas and 4 PTLD. Non-small cell carcinomas included 3 cases of squamous cell carcinoma and 2 cases of adenocarcinoma (Figure [1A](#F1){ref-type="fig"}). PTLD included 1 case of diffuse large B-cell lymphoma, 1 case of lymphomatoid granulomatosis (Figure [1B-C](#F1){ref-type="fig"}) and 2 cases of post transplant B-cell lymphoproliferative disorders. Diffuse parenchymal lung disease was identified in 9 (0.4%) cases. In 2 cases, pulmonary hemorrhage (PH) was the sole histological finding. In 1 case PH was associated with capillaritis. In 1 case PH was associated with pulmonary alveolar proteinosis (PAP) and in 1 case with diffuse alveolar damage (DAD). PH associated with capillaritis was documented in a patient with WG and was considered a pulmonary manifestation of the disease. Organizing pneumonia (OP) as the main histological finding was identified in 3 cases and PAP was identified in 1 case. Five (0.2%) cases showed histological features indicative of an infectious process including tissue necrosis, necrotic cellular debris, acute inflammation, and granulomas. In 1 of 5 cases, granulomatous inflammation was associated with *Pneumocystis jiroveci*(Figure [1D](#F1){ref-type="fig"}). Lung biopsy showed minimal findings in 5 (0.2%) patients.

![**Neoplastic and non-neoplastic localized lesions in renal transplant recipients**. (A) adenocarcinoma with predominantly micropapillary pattern (case 22, hematoxylin-eosin, original magnification x200); (B) lymphomatoid granulomatosis showing angiocentric proliferation of atypical lymphoid cells associated with Epstein-Bar virus (C), (case 25, hematoxylin-eosin and colorimetric in situ hybridization, original magnification x200 and x400, respectively); necrotizing granuloma (D) associated with *Pneumocystis jiroveci*(case 21, hematoxylin-eosin and Gomori methenamine silver, inset, original magnification x100 and x600, respectively).](1746-1596-7-25-1){#F1}

Clinicopathological findings in patients on sirolimus
-----------------------------------------------------

All patients with a lung tissue diagnosis received combination immunosuppressive therapy. The immunosuppressive regimen of 16 of 28 (57%) patients included sirolimus (Table [2](#T2){ref-type="table"}). Other immunosuppressants were comprised of cyclosporine (25/28; 89%), prednisone (23/28; 82%), dexamethasone (4/28; 14%), mycophenolate mofetil (6/28; 21%), and mycophenolic acid (2/28; 7%). The groups of patients receiving sirolimus versus other immunosuppressive medications were of similar age and gender (Table [2](#T2){ref-type="table"}). However, the mean time from the transplant to lung biopsy of patients on sirolimus was shorter (44.7 ± 52.04 vs. 128.3 ± 89.32, *p*= 0.01). Patients on sirolimus less frequently than patients on other immunosuppressants had neoplasia (12.5% vs. 58.3%, *p*= 0.03). Tumors in patients on sirolimus included 1 squamous cell carcinoma and 1 post transplant B-cell lymphoproliferative disorder. Tumors in the non-sirolimus group included 2 adenocarcinomas, 2 squamous cell carcinomas, 1 posttransplant B-cell lymphoproliferative disorders, 1 diffuse large B-cell lymphoma and 1 lymphomatoid granulomatosis. Patients on sirolimus had a tendency to have diffuse parenchymal lung disease (37.5% vs. 25.0%), including hemorrhage (25.0% vs.8.3%). The results, although suggestive of an association, did not achieve statistical significance.

###### 

Clinicopathological findings in patients on sirolimus versus other immunosuppressive therapy

                                            Sirolimus n = 16   Non-Sirolimus n = 12   P, value
  ----------------------------------------- ------------------ ---------------------- ----------
  Age, mean, years                          51.1 ± 13.25       54.3 ± 15.39           ns
                                                                                      
  Gender, M\*                               10 (62.5)          8 (66.7)               ns
                                                                                      
   F                                        6 (37.5)           4 (33.3)               ns
                                                                                      
  Time to lung biopsy, mean, months         44.7 ± 52.04       128.3 ± 89.32          0.01
                                                                                      
  Neoplasia, total, n (%)                   2 (12.5)           7 (58.3)               0.03
                                                                                      
   Carcinoma, n (%)                         1 (6.25)           4 (33.3)               ns
                                                                                      
   Lymphoproliferative disorders, n (%)     1 (6.25)           3 (25.0)               ns
                                                                                      
  Diffuse parenchymal lung disease, n (%)   6 (37.5)           3 (25.0)               ns
                                                                                      
   PH, n (%)                                2 (12.5)           1 (8.3)                ns
                                                                                      
   PH and DAD, n (%)                        1 (6.25)           0                      \-
                                                                                      
   PH and PAP, OP, n (%)                    1 (6.25)           0                      \-
                                                                                      
   OP, n (%)                                2 (12.5)           1 (8.3)                ns
                                                                                      
   PAP, n (%)                               0                  1 (8.3)                \-
                                                                                      
  Necrosis/infectious granulomas, n (%)     4 (25.0)           1 (8.3)                ns
                                                                                      
  Minimal histological findings, n (%)      4 (25.0)           1 (8.3)                ns

(\*) -*M*male; *F*female; *PH*pulmonary hemorrhage; *DAD*diffuse alveolar damage; *PAP*pulmonary alveolar proteinosis; *OP*organizing pneumonia; ns, not statistically significant

Sirolimus toxicity and response to treatment modification
---------------------------------------------------------

Sirolimus toxicity was suspected clinically in 5 (31.3%) of 16 patients. Their mean trough sirolimus levels were not statistically different from the other 10 cases on sirolimus (10.3 ± 5.72 ng/ml vs. 7.6 ± 3.56 ng/ml). Among these 5 cases, lung biopsies in 4 revealed pulmonary hemorrhage and OP, in 1. All 5 patients showed clinical and radiological improvement after the drug discontinuation. Their clinical course and response to treatment modification is detailed below.

In case 4, a 54 year old woman was admitted with recurrent shortness of breath for the fourth time in the five months following kidney transplant. The patient had a past medical history of chronic obstructive pulmonary disease and congestive heart failure with basic oxygen requirements of 3-4 l via nasal cannula. On her current admission she was in severe respiratory failure, requiring mechanical ventilation. Her trough sirolimus levels following transplantation were within range from 4.0 to 17.1, (mean, 8.8), normal 3-20 ng/ml. A chest CT on admission showed diffuse ground glass opacities and pleural effusions. Endobronchial biopsy was nondiagnostic, while a subsequent open lung biopsy showed collections of hemosiderin laden macrophages occupying alveolar spaces as well as hemosiderin granules within interstitium (Figure [2A](#F2){ref-type="fig"}). Evaluation for infectious organisms and vasculitis was negative. Since treatment for infection did not produce any significant improvement, sirolimus toxicity was suspected and sirolimus was discontinued. The patient returned to baseline respiratory status (3-4 l of oxygen) with improvements in bilateral opacities radiologically within 6 months. Following discharge, the patient required a single readmission for respiratory symptoms over the subsequent 33 months. At that time she was admitted for respiratory failure and subsequently expired. Postmortem examination revealed extensive hemosiderin deposition and a left upper lobe adenocarcinoma.

![**Pathological findings in patients with sirolimus toxicity**. In case 4, open lung biopsy shows diffuse alveolar hemorrhage represented by collections of hemosiderin laden alveolar macrophages (A, inset) and occasional hemosiderin granules within interstitium, (hematoxylin-eosin, original magnification x100 and x400, respectively). In case 10, open lung biopsy shows pulmonary hemorrhage in association with pulmonary alveolar proteinosis and organizing pneumonia: there are areas with hemosiderin deposition within interstitium (B) and cholesterol granulomas, finely granular proteinaceous material with cholesterol clefting (C) and foci of organizing pneumonia (D) in adjacent alveolar parenchyma, (hematoxylin-eosin, original magnification x100, x200 and × 40, respectively). Computed tomography of the chest at the time of open lung biopsy shows diffuse ground glass and \"crazy pavement\" opacities (E). Follow up computed tomography in 8 months (F) shows marked decrease in alveolar opacities; both scans are at the level of aortic arch for comparison. In case 16, open lung biopsy shows a combination of diffuse alveolar damage and pulmonary hemorrhage: there are edematous alveolar septae lined by hyaline membranes (G) and hemosiderin-laden macrophages (H) within alveolar spaces (H&E, original magnification x200 and x400, respectively).](1746-1596-7-25-2){#F2}

Case 10 is that of a 39-year-old African-American male, 80 months post kidney transplantation, hospitalized for increasing shortness of breath with increasing creatinine levels. His progressive hypoxia resulted in intubation. A chest CT showed diffuse bilateral ground glass opacities, \"crazy pavement\" pattern and focal nodular consolidation. His trough sirolimus levels within 6 months prior to admission were 8.1-11.8, (mean, 10.2) normal, 3-20 ng/ml. Hemosiderin laden macrophages associated with rare cholesterol granulomas were seen on transbronchial biopsy. His respiratory status continued to deteriorate and open lung biopsy was performed that showed alveolar and interstitial hemosiderin deposition accompanied by patchy organizing pneumonia, cholesterol granulomas and eosinophilic proteinaceous granular material (Figure [2B-D](#F2){ref-type="fig"}). The findings were compatible with a combination of PH and PAP. He underwent therapeutic bronchioloalveolar lavage and the decision was made to discontinue all immunosuppressive medications other than prednisone. During his nearly 2 month hospital stay, he was gradually weaned from ventilation support and his oxygen requirement at the time of discharge was 2 l of oxygen. Over the ensuing 8 months he showed clinical and radiological improvement (Figure [2E-F](#F2){ref-type="fig"}) on mycophenolate maintenance therapy. At 3.5 years of follow up, the patient was on maintenance mycophenolate therapy, had intermittent problems with recurrent lower respiratory tract infections, residual restrictive lung disease, and continued to use 2-3 l of oxygen via nasal cannula mostly with exercise.

Case 12 represents a 58-year old female who was hospitalized 24 months post kidney transplantation with shortness of breath, hypoxia, and renal failure. Her trough sirolimus level before admission was elevated to 19.7 ng/ml, normal 3-15 ng/ml. A bronchoscopic biopsy revealed occasional hemosiderin granules. Her symptoms did not improve and an open lung biopsy revealed histological evidence of PH with alveolar and interstitial hemosiderin deposition. Respiratory and blood cultures remained negative throughout the patient\'s stay. Sirolimus was stopped and over the following 4 months she showed significant clinical improvement despite continued baseline oxygen requirements.

Case 16 is that of a 34-year old female who was admitted in respiratory failure 17 months post kidney-pancreas transplant with two episodes of acute rejection. Her trough sirolimus levels were within range 2.4-6.7 ng/ml, mean 4.2 ng/ml, normal 3-15 ng/ml. Hemosiderin laden macrophages were present in the bronchioalveolar lavage fluid. Sirolimus toxicity was suspected and sirolimus was discontinued. Despite extensive work-up for infectious and rheumatologic etiologies and treatment with wide spectrum antibiotics she remained in respiratory failure. An open lung biopsy showed a combination of DAD and PH with hyaline membranes, architectural simplification with alveolar septal collapse, diffuse myxoid thickening, type 2 pneumocyte hyperplasia, and alveolar and interstitial hemosiderin (Figure [2G-H](#F2){ref-type="fig"}). The patient\'s treatment also included mechanical ventilation, volume and blood pressure control. After 2 months at a rehabilitation facility, her shortness of breath and cough were significantly improved and chest CT revealed resolution of the bilateral infiltrates. On further follow-up, the patient reported minimal respiratory symptoms.

Case 28 represents a 31-year-old male, 220 months post kidney transplantation, started to experience cough and dyspnea. He received a course of antibiotics for community-acquired pneumonia with no improvement. His trough sirolimus levels within previous 6 months were 4.4-13.2 ng/ml, (mean 8.6 ng/ml), normal 5-30 ng/ml. He underwent an extensive evaluation including a CT scan of the chest revealing extensive ground glass densities in a multifocal distribution. Evaluation for collagen vascular disease and infectious etiologies were negative, including a bronchoscopic examination with microbiological cultures. Transbronchial lung biopsy showed patchy organizing pneumonia and chronic inflammation. Since no systemic or infectious causes for his symptoms were found, sirolimus toxicity was suspected. Sirolimus was discontinued and he was given a course of oral corticosteroids. Over the following 2 months, his respiratory status improved significantly, with no reported shortness of breath, cough or wheezing and discontinuation of supplemental oxygen.

Discussion
==========

Kidney transplant recipients are known to be at increased risk for malignancy with up to 2 fold increased incidence rates for lung cancer and 20-fold increased incidence rates of PTLD \[[@B5]\]. Our retrospective review shows a wide spectrum of neoplastic and non-neoplastic lesions in the lungs of kidney transplant recipients on current immunosuppressive regimens. Among the neoplastic lesions there were 5 cases of non-small cell lung carcinoma and 4 cases of PTLD with incidence of approximately 0.2% each. The incidence of lung carcinoma in our series was similar to what was previously reported in other single center cohorts \[[@B27],[@B28]\], exceeding the incidence seen in general population \[[@B5]\]. The incidence of PTLD was lower, which is likely due to the fact that our study examined only lung biopsies and therefore couldn\'t account for the PTLD involving other sites. PTLD reportedly affects 1.8% of patients with up to 50% of cases presenting with extranodal masses, including lung nodules \[[@B29]-[@B31]\].

When correlated to the type of immunosuppression, the frequency of neoplasia in patents on sirolimus was lower (12.5% vs. 58.3%, *p*= 0.03) relative to patients on other immunosuppressants. It is possible that the longer transplant to lung biopsy time in the non-sirolimus group may have contributed to increased tumor detection. Nevertheless, our findings are in agreement with studies supporting antineoplastic properties of mTOR inhibitors in pre-clinical testing \[[@B9],[@B32],[@B33]\] and clinical studies of patients with post transplant solid organ tumors \[[@B28],[@B34]-[@B36]\], suggesting that sirolimus may be beneficial in preventing posttransplant malignancies.

Our study also demonstrates that pulmonary hemorrhage is a common histological finding in cases with clinically suspected sirolimus toxicity. In this cohort, it can be seen as the sole histological finding or in combination with other histological patterns including DAD and PAP. Based on their own experience and review of the literature, Pham and colleagues list pulmonary hemorrhage, organizing pneumonia, and lymphocytic pneumonitis among the most common histological patterns of sirolimus toxicity \[[@B18]\]. From a clinical management point of view, the histological diagnosis of pulmonary hemorrhage carries a task of elucidating its possible causes which generally include alveolar hemorrhage syndromes or secondary causes associated with infections, toxic inhalation, coagulopathies, renal failure with volume overload, and venous congestion due to heart disease to name a few \[[@B37]\]. In our series only one case with PH was linked to Wegener\'s granulomatosis. During their clinical course, the study patients experienced renal failure with wide fluctuation of serum creatinine levels; however, the renal function was generally well controlled, and none had clinically documented sustained fluid overload. In our cases pulmonary hemorrhage could not be explained by any other causes, and sirolimus discontinuation lead to the gradual clinical improvement. In case 4, the patient had congestive heart failure, which histologically can be associated with pulmonary hemosiderin deposition. Therefore, it is difficult to completely exclude the contribution of the patient\'s underlying heart disease to the observed histological findings. In that regard, this case is similar to that reported by Hashemi-Sadraei N and colleagues \[[@B38]\]. They described a renal transplant recipient who was on chronic anticoagulation therapy for a prosthetic aortic valve, and who developed pulmonary symptoms following initiation of sirolimus therapy. An open lung biopsy showed diffuse alveolar hemorrhage with fibrin deposits in the alveolar spaces and small bronchi. Even though the underlying disease, congestive heart failure or heart valve requiring anticoagulation therapy, may have contributed to the pulmonary hemosiderin deposition, in both of these cases the response to sirolimus discontinuation suggests a causative association between the drug and pulmonary hemorrhage.

Other histological patterns identified within a spectrum of the diffuse parenchymal lung disease in patients on sirolimus were OP, DAD, and PAP. The spectrum of etiologic considerations in OP includes infection, collagen vascular disease, toxic inhalation, aspiration pneumonia, hypersensitivity pneumonitis, and drug toxicity \[[@B39],[@B40]\]. Additionally, OP can be a minor component of other interstitial lung diseases. OP is one of the relatively frequently reported manifestations of sirolimus toxicity \[[@B18]\]. We identified OP as a main histological feature in 3 cases; however, it was also observed as a minor component in other cases including cases of pulmonary hemorrhage and DAD. This could be a reason for some discrepancy between reported frequencies of OP, especially if a diagnosis is rendered on a small endobronchial or transbronchial biopsy \[[@B18]\]. DAD is a well recognized histological pattern known to be associated with drug toxicity \[[@B41]\]. Among tissue reactions associated with sirolimus toxicity, only one case of DAD has been documented in the literature. Manito and colleagues \[[@B26]\] reported a fatal course of DAD in a 52-year-old man heart transplant recipient following a loading-dose of sirolimus administration. We observed DAD in one patient on sirolimus (case 16) where an open lung biopsy revealed a combination of DAD and pulmonary hemorrhage. No infectious or systemic disease was documented with extensive clinical evaluation. Despite wide spectrum antibiotics coverage, the patient showed a protracted clinical course but gradually improved over 2 months after sirolimus discontinuation showing only minimal pulmonary symptoms.

PAP is a rare poorly understood disorder that is characterized by accumulation of lipoproteinaceous surfactant-like material within alveolar parenchyma. Impaired macrophage function due to antibodies to granulocyte macrophage-colony stimulating factor is thought to be a key mechanism in primary PAP. Macrophage dysfunction due to immunosuppression is considered as one among many other causes of secondary PAP. It has been linked to sirolimus toxicity in 2 previously reported cases \[[@B22],[@B42]\]. PAP histology in our series was documented in both sirolimus (1 case) and non-sirolimus (1 case) groups, suggesting that this is a secondary immunosuppression related tissue reaction that is not directly related to sirolimus toxicity.

Sirolimus induced immunosuppression results from the inhibition of T and B lymphocyte proliferation through the same mechanisms as it inhibits cancer cell proliferation. These effects are thought to be mediated through the rapamycin-FKPB12 complex altering the mTOR signaling network which includes tumor suppressor genes (PTEN, LKB1, TSC1, and TSC2) and proto-oncogenes (PI3K, Akt, and eIF4E) \[[@B43]\]. While the exact mechanisms of sirolimus toxicity are not known, several hypotheses have emerged. Clinical improvement after sirolimus dose reduction provides evidence for a dose-dependant pulmonary toxicity. Clinically and radiologically documented pneumonitis in kidney transplant recipients has been reported to improve dramatically after sirolimus dose reduction and the maintenance of lower trough levels \[[@B44]\]. BAL fluid analysis in cases of the drug induced alveolitis showed a predominance of CD4-positive lymphocytes allowing the authors to suggest that a cell mediated autoimmune response may be one of the factors responsible for sirolimus induced pulmonary toxicity \[[@B44]\]. Furthermore, it has been speculated that the drug\'s high affinity for plasma proteins may render sirolimus immunogenic as a hapten eliciting cascade of T-cell mediated delayed type of hypersensitivity reaction \[[@B18]\]. These hypotheses appear to capture the state of current knowledge; however, detailed mechanisms of sirolimus toxicity and their relationship to the spectrum of histological patterns of parenchymal lung disease are yet to be elucidated.

Conclusions
===========

Our study documents that kidney transplant recipients show a range of pulmonary neoplastic and non-neoplastic lesions, which are likely associated with the type of immunosuppressive regimen. Current mTOR inhibitor inclusive regimens may account for decreased number of tumors in kidney transplant recipients but also carry a risk of pulmonary toxicity manifesting histologically by pulmonary hemorrhage, organizing pneumonia and other less common histological patterns.
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